Ocugen reports Q3 revenue $1.136M, consensus $300,000

Reports Q3 net income ($12.97M) vs ($11.72M) last year. The Company’s cash and restricted cash totaled $39.0M as of September 30, compared to $39.5M as of December 31, 2023. “I am very encouraged by the progress of our gene therapy programs and the clinical and regulatory milestones achieved in the Q3, including the expansion of the OCU400 Phase 3 liMeliGhT clinical trial into Canada,” said Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen (OCGN). “With the recent equity and debt financings, we have sufficient cash-on-hand to continue supporting our robust ophthalmology pipeline and extend our cash runway into Q1 of FY26.”